Full Text View
Tabular View
Study Results
Related Studies
Azacitidine in Treating Patients With Myelofibrosis
This study has been terminated.
( Due to lack of accrual and trial has demonstrated too little clinical benefit )
Study NCT00381693   Information provided by Mayo Clinic

First Received on September 26, 2006.   Last Updated on April 19, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Secondary Myelofibrosis
Additional conditions recognized in this trial
Myeloproliferative Disorders
Primary Myelofibrosis
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Interventions listed in this trial
azacitidine
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Mayo Clinic
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services